Obesity Treatment Market Size, Share & Trends Report

Obesity Treatment Market Size, Share & Trends Analysis Report By Drug Class (GLP-1 Receptor Agonists, Lipase Inhibitors, Appetite Suppressants), By Route Of Administration (Parenteral, Oral), By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030

Report ID: GVR-1-68038-095-8
Number of Report Pages: 153
Format: PDF

Historical Range: 2018 - 2024
Forecast Period: 2025 - 2030
Industry: Healthcare

Market Segmentation

Treatment Drug Class Outlook (Revenue, USD Million, 2018 - 2030)
- GLP-1 Receptor Agonists
  - Semaglutide (Wegovy)
  - Liraglutide (Saxenda)
  - Tirzepatide (Zepbound)
- Lipase Inhibitors
- Appetite Suppressants
- Other Drug Class
Treatment Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
- Parenteral
- Oral
Treatment Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)
- Hospital Pharmacies
- Retail Pharmacies
- Others
Treatment Market Regional Outlook (Revenue, USD Million, 2018 - 2030)
- North America
  - North America Obesity Treatment Market, Drug Class
    - GLP-1 Receptor Agonists
      - Semaglutide (Wegovy)
      - Liraglutide (Saxenda)
      - Tirzepatide (Zepbound)
    - Lipase Inhibitors
    - Appetite Suppressants
    - Other Drug Class
  - North America Obesity Treatment Market, Route of Administration
    - Parenteral
    - Oral
  - North America Obesity Treatment Market, Distribution Channel
    - Hospital Pharmacies
    - Retail Pharmacies
    - Others
  - U.S.
    - U.S. Obesity Treatment Market, Drug Class
      - GLP-1 Receptor Agonists
        
        Semaglutide (Wegovy)
        
        Liraglutide (Saxenda)
        
        Tirzepatide (Zepbound)
      - Lipase Inhibitors
      - Appetite Suppressants
      - Other Drug Class
    - U.S. Obesity Treatment Market, Route of Administration
      - Parenteral
      - Oral
      - Others
    - U.S. Obesity Treatment Market, Distribution Channel
      - Hospital Pharmacies
      - Retail Pharmacies
      - Others
  - Canada
    - Canada Obesity Treatment Market, Drug Class
      - GLP-1 Receptor Agonists
        
        Semaglutide (Wegovy)
        
        Liraglutide (Saxenda)
        
        Tirzepatide (Zepbound)
      - Lipase Inhibitors
      - Appetite Suppressants
      - Other Drug Class
    - Canada Obesity Treatment Market, Route of Administration
      - Parenteral
      - Oral
      - Others
    - Canada Obesity Treatment Market, Distribution Channel
      - Hospital Pharmacies
      - Retail Pharmacies
      - Others
  - Mexico
    - Mexico Obesity Treatment Market, Drug Class
      - GLP-1 Receptor Agonists
        
        Semaglutide (Wegovy)
        
        Liraglutide (Saxenda)
        
        Tirzepatide (Zepbound)
      - Lipase Inhibitors
      - Appetite Suppressants
      - Other Drug Class
    - Mexico Obesity Treatment Market, Route of Administration
      - Parenteral
      - Oral
      - Others
    - Mexico Obesity Treatment Market, Distribution Channel
      - Hospital Pharmacies
      - Retail Pharmacies
      - Others
- Europe
  - Europe Obesity Treatment Market, Drug Class
    - GLP-1 Receptor Agonists
      - Semaglutide (Wegovy)
      - Liraglutide (Saxenda)
      - Tirzepatide (Zepbound)
    - Lipase Inhibitors
    - Appetite Suppressants
    - Other Drug Class
  - Europe Obesity Treatment Market, Route of Administration
    - Parenteral
    - Oral
    - Others
  - Europe Obesity Treatment Market, Distribution Channel
    - Hospital Pharmacies
    - Retail Pharmacies
    - Others
  - U.K.
    - U.K. Obesity Treatment Market, Drug Class
      - GLP-1 Receptor Agonists
        
        Semaglutide (Wegovy)
        
        Liraglutide (Saxenda)
        
        Tirzepatide (Zepbound)
      - Lipase Inhibitors
      - Appetite Suppressants
      - Other Drug Class
    - U.K. Obesity Treatment Market, Route of Administration
      - Parenteral
      - Oral
      - Others
    - U.K. Obesity Treatment Market, Distribution Channel
      - Hospital Pharmacies
      - Retail Pharmacies
      - Others
  - Germany
    - Germany Obesity Treatment Market, Drug Class
      - GLP-1 Receptor Agonists
        
        Semaglutide (Wegovy)
        
        Liraglutide (Saxenda)
        
        Tirzepatide (Zepbound)
      - Lipase Inhibitors
      - Appetite Suppressants
      - Other Drug Class
    - Germany Obesity Treatment Market, Route of Administration
      - Parenteral
      - Oral
      - Others
    - Germany Obesity Treatment Market, Distribution Channel
      - Hospital Pharmacies
      - Retail Pharmacies
      - Others
  - France
    - France Obesity Treatment Market, Drug Class
      - GLP-1 Receptor Agonists
        
        Semaglutide (Wegovy)
        
        Liraglutide (Saxenda)
        
        Tirzepatide (Zepbound)
      - Lipase Inhibitors
      - Appetite Suppressants
      - Other Drug Class
    - France Obesity Treatment Market, Route of Administration
      - Parenteral
      - Oral
      - Others
    - France Obesity Treatment Market, Distribution Channel
      - Hospital Pharmacies
      - Retail Pharmacies
      - Others
  - Italy
    - Italy Obesity Treatment Market, Drug Class
      - GLP-1 Receptor Agonists
        
        Semaglutide (Wegovy)
        
        Liraglutide (Saxenda)
        
        Tirzepatide (Zepbound)
      - Lipase Inhibitors
      - Appetite Suppressants
      - Other Drug Class
    - Italy Obesity Treatment Market, Route of Administration
      - Parenteral
      - Oral
      - Others
    - Italy Obesity Treatment Market, Distribution Channel
      - Hospital Pharmacies
      - Retail Pharmacies
      - Others
  - Spain
    - Spain Obesity Treatment Market, Drug Class
      - GLP-1 Receptor Agonists
        
        Semaglutide (Wegovy)
        
        Liraglutide (Saxenda)
        
        Tirzepatide (Zepbound)
      - Lipase Inhibitors
      - Appetite Suppressants
      - Other Drug Class
    - Spain Obesity Treatment Market, Route of Administration
      - Parenteral
      - Oral
      - Others
    - Spain Obesity Treatment Market, Distribution Channel
      - Hospital Pharmacies
      - Retail Pharmacies
      - Others
    - Denmark
      - Denmark Obesity Treatment Market, Drug Class
        
        GLP-1 Receptor Agonists
        
        Semaglutide (Wegovy)
        
        Liraglutide (Saxenda)
        
        Tirzepatide (Zepbound)
        
        Lipase Inhibitors
        
        Appetite Suppressants
        
        Other Drug Class
      - Denmark Obesity Treatment Market, Route of Administration
        
        Parenteral
        
        Oral
        
        Others
      - Denmark Obesity Treatment Market, Distribution Channel
        
        Hospital Pharmacies
        
        Retail Pharmacies
        
        Others
  - Sweden
    - Sweden Obesity Treatment Market, Drug Class
      - GLP-1 Receptor Agonists
        
        Semaglutide (Wegovy)
        
        Liraglutide (Saxenda)
        
        Tirzepatide (Zepbound)
      - Lipase Inhibitors Appetite Suppressants
      - Other Drug Class
    - Sweden Obesity Treatment Market, Route of Administration
      - Parenteral
      - Oral
      - Others
    - Sweden Obesity Treatment Market, Distribution Channel
      - Hospital Pharmacies
      - Retail Pharmacies
      - Others
  - Norway
    - Norway Obesity Treatment Market, Drug Class
      - GLP-1 Receptor Agonists
        
        Semaglutide (Wegovy)
        
        Liraglutide (Saxenda)
        
        Tirzepatide (Zepbound)
      - Lipase Inhibitors
      - Appetite Suppressants
      - Other Drug Class
    - Norway Obesity Treatment Market, Route of Administration
      - Parenteral
      - Oral
      - Others
    - Norway Obesity Treatment Market, Distribution Channel
      - Hospital Pharmacies
      - Retail Pharmacies
      - Others
- Asia Pacific
  - Asia Pacific Obesity Treatment Market, Drug Class
    - GLP-1 Receptor Agonists
      - Semaglutide (Wegovy)
      - Liraglutide (Saxenda)
      - Tirzepatide (Zepbound)
    - Lipase Inhibitors
    - Appetite Suppressants
    - Other Drug Class
  - Asia Pacific Obesity Treatment Market, Route of Administration
    - Parenteral
    - Oral
    - Others
  - Asia Pacific Obesity Treatment Market, Distribution Channel
    - Hospital Pharmacies
    - Retail Pharmacies
    - Others
  - China
    - China Obesity Treatment Market, Drug Class
      - GLP-1 Receptor Agonists
        
        Semaglutide (Wegovy)
        
        Liraglutide (Saxenda)
        
        Tirzepatide (Zepbound)
      - Lipase Inhibitors
      - Appetite Suppressants
      - Other Drug Class
    - China Obesity Treatment Market, Route of Administration
      - Parenteral
      - Oral
      - Others
    - China Obesity Treatment Market, Distribution Channel
      - Hospital Pharmacies
      - Retail Pharmacies
      - Others
  - Japan
    - Japan Obesity Treatment Market, Drug Class
      - GLP-1 Receptor Agonists
        
        Semaglutide (Wegovy)
        
        Liraglutide (Saxenda)
        
        Tirzepatide (Zepbound)
      - Lipase Inhibitors
      - Appetite Suppressants
      - Other Drug Class
    - Japan Obesity Treatment Market, Route of Administration
      - Parenteral
      - Oral
      - Others
    - Japan Obesity Treatment Market, Distribution Channel
      - Hospital Pharmacies
      - Retail Pharmacies
      - Others
  - India
    - India Obesity Treatment Market, Drug Class
      - GLP-1 Receptor Agonists
        
        Semaglutide (Wegovy)
        
        Liraglutide (Saxenda)
        
        Tirzepatide (Zepbound)
      - Lipase Inhibitors
      - Appetite Suppressants
      - Other Drug Class
    - India Obesity Treatment Market, Route of Administration
      - Parenteral
      - Oral
      - Others
    - India Obesity Treatment Market, Distribution Channel
      - Hospital Pharmacies
      - Retail Pharmacies
      - Others
  - Australia
    - Australia Obesity Treatment Market, Drug Class
      - GLP-1 Receptor Agonists
        
        Semaglutide (Wegovy)
        
        Liraglutide (Saxenda)
        
        Tirzepatide (Zepbound)
      - Lipase Inhibitors
      - Appetite Suppressants
      - Other Drug Class
    - Australia Obesity Treatment Market, Route of Administration
      - Parenteral
      - Oral
      - Others
    - Australia Obesity Treatment Market, Distribution Channel
      - Hospital Pharmacies
      - Retail Pharmacies
      - Others
  - South Korea
    - South Korea Obesity Treatment Market, Drug Class
      - GLP-1 Receptor Agonists
        
        Semaglutide (Wegovy)
        
        Liraglutide (Saxenda)
        
        Tirzepatide (Zepbound)
      - Lipase Inhibitors
      - Appetite Suppressants
      - Other Drug Class
    - South Korea Obesity Treatment Market, Route of Administration
      - Parenteral
      - Oral
      - Others
    - South Korea Obesity Treatment Market, Distribution Channel
      - Hospital Pharmacies
      - Retail Pharmacies
      - Others
  - Thailand
    - Thailand Obesity Treatment Market, Drug Class
      - GLP-1 Receptor Agonists
        
        Semaglutide (Wegovy)
        
        Liraglutide (Saxenda)
        
        Tirzepatide (Zepbound)
      - Lipase Inhibitors
      - Appetite Suppressants
      - Other Drug Class
    - Thailand Obesity Treatment Market, Route of Administration
      - Parenteral
      - Oral
      - Others
    - Thailand Obesity Treatment Market, Distribution Channel
      - Hospital Pharmacies
      - Retail Pharmacies
      - Others
- Latin America
  - Latin America Obesity Treatment Market, Drug Class
    - GLP-1 Receptor Agonists
      - Semaglutide (Wegovy)
      - Liraglutide (Saxenda)
      - Tirzepatide (Zepbound)
    - Lipase Inhibitors
    - Appetite Suppressants
    - Other Drug Class
  - Latin America Obesity Treatment Market, Route of Administration
    - Parenteral
    - Oral
    - Others
  - Latin America Obesity Treatment Market, Distribution Channel
    - Hospital Pharmacies
    - Retail Pharmacies
    - Others
  - Brazil
    - Brazil Obesity Treatment Market, Drug Class
      - GLP-1 Receptor Agonists
        
        Semaglutide (Wegovy)
        
        Liraglutide (Saxenda)
        
        Tirzepatide (Zepbound)
      - Lipase Inhibitors
      - Appetite Suppressants
      - Other Drug Class
    - Brazil Obesity Treatment Market, Route of Administration
      - Parenteral
      - Oral
      - Others
    - Brazil Obesity Treatment Market, Distribution Channel
      - Hospital Pharmacies
      - Retail Pharmacies
      - Others
  - Argentina
    - Argentina Obesity Treatment Market, Drug Class
      - GLP-1 Receptor Agonists
        
        Semaglutide (Wegovy)
        
        Liraglutide (Saxenda)
        
        Tirzepatide (Zepbound)
      - Lipase Inhibitors
      - Appetite Suppressants
      - Other Drug Class
    - Argentina Obesity Treatment Market, Route of Administration
      - Parenteral
      - Oral
      - Others
    - Argentina Obesity Treatment Market, Distribution Channel
      - Hospital Pharmacies
      - Retail Pharmacies
      - Others
- Middle East & Africa
  - Middle East & Africa Obesity Treatment Market, Drug Class
    - GLP-1 Receptor Agonists
      - Semaglutide (Wegovy)
      - Liraglutide (Saxenda)
      - Tirzepatide (Zepbound)
    - Lipase Inhibitors
    - Appetite Suppressants
    - Other Drug Class
  - Middle East & Africa Obesity Treatment Market, Route of Administration
    - Parenteral
    - Oral
    - Others
  - Middle East & Africa Obesity Treatment Market, Distribution Channel
    - Hospital Pharmacies
    - Retail Pharmacies
    - Others
  - South Africa
    - South Africa Obesity Treatment Market, Drug Class
      - GLP-1 Receptor Agonists
        
        Semaglutide (Wegovy)
        
        Liraglutide (Saxenda)
        
        Tirzepatide (Zepbound)
      - Lipase Inhibitors
      - Appetite Suppressants
      - Other Drug Class
    - South Africa Obesity Treatment Market, Route of Administration
      - Parenteral
      - Oral
      - Others
    - South Africa Obesity Treatment Market, Distribution Channel
      - Hospital Pharmacies
      - Retail Pharmacies
      - Others
  - Saudi Arabia
    - Saudi Arabia Obesity Treatment Market, Drug Class
      - GLP-1 Receptor Agonists
        
        Semaglutide (Wegovy)
        
        Liraglutide (Saxenda)
        
        Tirzepatide (Zepbound)
      - Lipase Inhibitors
      - Appetite Suppressants
      - Other Drug Class
    - Saudi Arabia Obesity Treatment Market, Route of Administration
      - Parenteral
      - Oral
      - Others
    - Saudi Arabia Obesity Treatment Market, Distribution Channel
      - Hospital Pharmacies
      - Retail Pharmacies
      - Others
  - UAE
    - UAE Obesity Treatment Market, Drug Class
      - GLP-1 Receptor Agonists
        
        Semaglutide (Wegovy)
        
        Liraglutide (Saxenda)
        
        Tirzepatide (Zepbound)
      - Lipase Inhibitors
      - Appetite Suppressants
      - Other Drug Class
    - UAE Obesity Treatment Market, Route of Administration
      - Parenteral
      - Oral
      - Others
    - UAE Obesity Treatment Market, Distribution Channel
      - Hospital Pharmacies
      - Retail Pharmacies
      - Others
  - Kuwait
    - Kuwait Obesity Treatment Market, Drug Class
      - GLP-1 Receptor Agonists
        
        Semaglutide (Wegovy)
        
        Liraglutide (Saxenda)
        
        Tirzepatide (Zepbound)
      - Lipase Inhibitors
      - Appetite Suppressants
      - Other Drug Class
    - Kuwait Obesity Treatment Market, Route of Administration
      - Parenteral
      - Oral
      - Others
    - Kuwait Obesity Treatment Market, Distribution Channel
      - Hospital Pharmacies
      - Retail Pharmacies
      - Others

Report content

Qualitative Analysis

Industry overview
Industry trends
Market drivers and restraints
Market size
Growth prospects
Porter’s analysis
PESTEL analysis
Key market opportunities prioritized
Competitive landscape
- Company overview
- Financial performance
- Product benchmarking
- Latest strategic developments

Quantitative Analysis

Market size, estimates, and forecast from 2018 to 2030
Market estimates and forecast for product segments up to 2030
Regional market size and forecast for product segments up to 2030
Market estimates and forecast for application segments up to 2030
Regional market size and forecast for application segments up to 2030
Company financial performance

GET A FREE SAMPLE

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

Or view our licence options:

NEED A CUSTOM REPORT?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

ESOMAR certified & member

ISO Certified

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.